Pancreatic cancer (PC) has a 5-year survival of less than 5%, which has remained unchanged for almost 50 years and persists as the 4th most common cause of cancer death in Western societies. Angela's PhD work focuses on developing personalised treatment approaches for pancreatic cancer. She has shown that a novel cyclin-dependent kinase inhibitor may be effective in targeting pancreatic cancers that harbour specific cell cycle aberrations. Given that these aberrations occur in >50% of pancreatic cancers, the potential for translation is significant, as a considerable proportion of patients may benefit from this type of therapy. Angela received the Postgraduate Research Award 2012, which has supported and funded her work in the beginning of her PhD. She is very grateful for the award, which has later helped her to be successful in receiving other awards and scholarships.